These biomarkers with further extensive validation may serve as biomarkers for the CDK4/6 inhibitors that are currently available for breast cancer patients with hormone receptor-positive metastatic/advanced breast cancer [11]. The gene discussed is NR4A1; the disease is breast carcinoma.